TriWise Capital
Venture capitalShenzhen · Pre-Seed–Late Stage · 1 people tracked
Investment thesis
TriWise Capital pursues a philosophy of 'investment returning to industry, capital serving industry,' emphasizing original and value investing across the healthcare ecosystem. It focuses on frontier technologies such as innovative drugs, cell and gene therapy, synthetic biology, biological breeding, and high-end medical devices. Leveraging partnerships with national medical device innovation centers, the Chinese Academy of Sciences Shenzhen Institute of Advanced Technology, and biomedical translation institutes, the firm targets early-stage companies with high growth potential and strong industry barriers. Its model combines roughly 30% investment with 70% services, effectively co-founding ventures with entrepreneurial teams and providing post-investment support to help commercialize scientific research results.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from the firm's websiteWhat they invest in
from 1 of 1 portfolio companiesBiotech ×1FemTech ×1Medical Devices ×1
HQs:China×1
Investments · 1 tracked
founders shown can be your intro pathAsieris (亚虹医药) is a pharmaceutical company developing diagnostic and therapeutic products focused on women's reproductive health and urologic cancers, including treatments for cervical precancerous lesions and bladder cancer.
BiotechFemTechMedical Devices
Co-investorsQiming Venture PartnersYF Capital
Frequently asked questions
- What stage does TriWise Capital invest at?
- TriWise Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does TriWise Capital focus on?
- TriWise Capital focuses on AgTech, AI & Machine Learning, Biotech, Climate Tech, Deep Tech, Digital Health, Hardware, Healthtech, Medical Devices, Semiconductors.
- Where is TriWise Capital located?
- TriWise Capital is headquartered in Shenzhen, CN.
- Does TriWise Capital lead rounds?
- Yes, TriWise Capital leads investment rounds.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Innovation Industries is a deep tech investor backing companies with ground-breaking technologies aimed at addressing fundamental global challenges, providing support to help them scale and maximize environmental, social, and economic impact.
Green Pine Capital Partners is a Chinese venture and technology investment firm with over two decades of history investing in technology companies, backing firms that have gone on to IPO.